Tolero Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Beta Cat Pharmaceuticals, Inc.

University of Utah Research Foundation

Stingray Therapeutics, Inc.

Xiaohui Liu

Koc-Kan Ho

Yong Xu

Michael David Saunders

Jihua Liu

Kenneth Mark Parnell

Steven G Kultgen

Jason Marc Foulks

Kevin Bret Wright

Benjamin Gary Brenning

Scott Albert Pearce

Steven Brian Kanner

David Lee Vollmer

Hariprasad Vankayalapati

Sunil Sharma

Srinivas Rao Kasibhatla

Seelam Venkata Reddy

Alexis Weston

Mohan Rao Kaadige

Trason Thode

Gurusankar Ramamoorthy

Hariprasad M Vankayalapati

Micheal David Saunders

The present invention provides a compound having the following structure: Compositions and methods for using the same in the treatment of skin disorders and other Pim kinase-associated conditions are also disclosed.

Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

PKM2 modulators and methods for their use

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.

Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics

The present invention provides substituted imidazo[1,2-b]pyridazines that are useful as protein kinase inhibitors and have one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R, Rand X are as defined herein. For example, a compound having the following structure:  Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R, Rand X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures; including, salts thereof that act as anti-cancer and anti-tumor agents, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Anthracene-9, 10-dione dioxime compound prodrugs and their uses

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R, Rand X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed. 

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Growing community of inventors

Holladay, UT, United States of America

Xiaohui Liu